Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026)
Relay Therapeutics (RLAY) posted quarterly Return on Capital Employed of 47.0% for Q1 2026, down 103.0% year-over-year from 1566.77% in Q1 2025, and up 3.73% quarter-over-quarter from 48.82% in Q4 2025.
Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Return on Capital Employed for 7 consecutive years, with 47.0% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 103.0% year-over-year to 47.0%; the TTM figure through Mar 2026 stood at 47.0% (down 103.0% YoY), while the FY2025 annual figure was 42.0%, up 416.0% from the prior year.
- Return on Capital Employed grew to 47.0% in Q1 2026 per RLAY's latest filing, from 48.82% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.96% in Q4 2022 and bottomed at 49.05% in Q3 2025.
- Historically, Return on Capital Employed has averaged 41.67% across 5 years, with a median of 44.13% in 2023.
- On a YoY basis, Return on Capital Employed climbed as much as 4799 bps in 2022 and fell as far as 97125 bps in 2022.
- Relay Therapeutics' Return on Capital Employed stood at 27.96% in 2022, then tumbled by 58 bps to 44.13% in 2023, then climbed by 1 bps to 43.82% in 2024, then declined by 11 bps to 48.82% in 2025, then grew by 4 bps to 47.0% in 2026.
- Business Quant data shows RLAY's Return on Capital Employed at 47.0% in Q1 2026, 48.82% in Q4 2025, and 49.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -39.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.66% |
| Mar 31, 2026 | -47.00% |
| Dec 31, 2025 | -48.82% |
| Sep 30, 2025 | -49.05% |
| Jun 30, 2025 | -46.89% |
| Mar 31, 2025 | -45.97% |
| Dec 31, 2024 | -43.82% |
| Sep 30, 2024 | -47.20% |
| Jun 30, 2024 | -46.84% |
| Mar 31, 2024 | -44.96% |
| Dec 31, 2023 | -44.13% |
| Sep 30, 2023 | -40.02% |
| Jun 30, 2023 | -39.43% |
| Mar 31, 2023 | -33.83% |
| Dec 31, 2022 | -27.96% |
| Sep 30, 2022 | -30.72% |
| Jun 30, 2022 | -30.74% |
| Mar 31, 2022 | -41.07% |
| Dec 31, 2021 | -75.94% |
| Sep 30, 2021 | 940.54% |